SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Innodata, Inc. is a data engineering company, which engages in providing artificial intelligence software platforms and management of its services. It operates through the following business segments: Digital Data Solutions (DDS), Synodex, and Agility. The DDS segment combines deep neural networks and human expertise in multiple domains to make unstructured information useable. The Synodex segment enables clients in the insurance and healthcare sectors to transform medical records into useable digital data and to apply technologies to the digital data to augment decision support. The Agility segment provides tools and related professional services that enable public relations and communications professionals to discover influencers, amplify messages, monitor coverage, and measure the impact of campaigns. The company was founded by Todd H. Solomon in 1988 and is headquartered in Ridgefield Park, NJ.

Innodata Inc

Innodata is trending due to its recent partnership with Palantir and strategic expansion into the burgeoning robotics and physical AI sectors, with many speculating on the impact of these developments ahead of its upcoming Q4 earnings report. While community members are discussing the company's critical role in training AI for big tech, government, and defense, its valuation and the broader market's tech sell-off are key talking points.

Based Chad

CHAD CRYPTO is trending as community enthusiasm surges, driven by prominent Coinbase executives and the Base lead developer actively supporting the token's ecosystem, which includes unique buyback and staking features, further solidifying its appeal as a universally recognized meme.

Magnite, Inc. provides a technology solution to automate the purchase and sale of digital advertising inventory for buyers and sellers. It features applications and services for digital advertising sellers including websites, mobile applications, and other digital media properties. The company was founded by Frank Addante, Duc Chau, Craig Roah, Julie Mattern and Brian D. Baumgart on April 20, 2007 and is headquartered in New York, NY.

Magnite Inc

Magnite is garnering significant attention as the ad tech community eagerly awaits potential market-shifting Google antitrust remedies, while discussing the company's robust Connected TV growth driven by key partnerships with platforms like Netflix and New York Times Advertising, which many believe makes the stock severely undervalued despite current market volatility.

Chainlink is the industry-standard decentralized oracle network that solves the "oracle problem" by connecting smart contracts with real-world data. Blockchains cannot access external information on their own, so Chainlink acts as a secure bridge, enabling smart contracts to react to real-world events using verified, tamper-proof data. It is widely considered one of the first decentralized oracle networks and is the market leader in bringing off-chain data on-chain.  The platform operates through a decentralized network of nodes that fetch, validate, and deliver data to smart contracts. When a contract requests information like a stock price, a committee of independent nodes retrieves and aggregates the data to reach consensus, then delivers a single trustworthy answer. Chainlink offers a suite of services including Data Feeds for asset prices, CCIP for cross-chain token transfers and messaging, Automation for triggering smart contract functions, and Proof of Reserve for verifying asset collateralization.  Chainlink has established itself as critical infrastructure for both DeFi and institutional adoption, with partnerships including Swift, Euroclear, Mastercard, UBS, ANZ, Fidelity International, and J.P. Morgan. Its institutional products include the Chainlink Runtime Environment for tokenized asset workflows, Confidential Compute for privacy-preserving computation, and the Automated Compliance Engine for embedding regulatory rules into smart contracts.  The LINK token is the native asset used to pay node operators for services, fund subscription accounts, and incentivize network security through staking. Node operators stake LINK as collateral, which can be slashed if they provide inaccurate data. Chainlink was co-founded in 2017 by Sergey Nazarov and Steve Ellis, who co-authored the white paper with Ari Juels, and raised $32 million in its September 2017 ICO.

ChainLink

Chainlink is trending due to its pivotal role in real-world asset tokenization, underscored by its adoption in Robinhood's Layer 2 testnet and upcoming CME futures. The community, while noting price frustrations, maintains high conviction that pending regulatory clarity will unlock significant institutional capital, cementing LINK as a critical financial backbone.

Ethereum is a global, open-source platform for decentralized applications. In other words, it is a decentralized blockchain platform that enables developers to build and deploy smart contracts and applications without central authority control. Unlike Bitcoin, which primarily functions as digital currency, Ethereum operates as a programmable global computer where developers can create any type of decentralized service.   The platform hosts over $14 billion in DeFi applications with hundreds of thousands of active users across financial protocols, NFT marketplaces, and gaming platforms. Its transition to Proof of Stake in September 2022 reduced energy consumption by over 99%, addressing environmental concerns while strengthening network security.  The network operates through thousands of independent validator nodes that process transactions and execute smart contracts on the Ethereum Virtual Machine. Smart contracts are self-executing programs written in Solidity that automatically carry out agreements when conditions are met, eliminating intermediaries like banks or brokers.   Validators stake ETH as collateral to propose and validate blocks, earning rewards for honest participation while facing penalties for malicious behavior. The EIP-1559 upgrade introduced a dynamic base fee mechanism that burns ETH with each transaction, creating deflationary pressure during high network activity when more ETH is burned than issued to validators.  Vitalik Buterin proposed Ethereum in 2013, but seven co-founders helped build it, including Gavin Wood who created Solidity and the EVM technical specification, and Joseph Lubin who founded ConsenSys. The project launched in July 2015 after raising over $18 million through crowdfunding, quickly becoming the largest blockchain developer community. Major milestones include the 2020 Beacon Chain launch, the 2021 London hard fork implementing fee burning, and the 2022 Merge to Proof of Stake.   Ether (ETH) serves multiple functions: paying transaction fees (gas), staking to secure the network and earn 3-5% annual yields, serving as collateral in DeFi protocols, and purchasing NFTs and digital assets. The asset is increasingly adopted by traditional institutions, with publicly traded companies adding ETH to corporate treasuries to generate staking yields while maintaining blockchain exposure, and in 2024, the SEC approved spot Ethereum ETFs, allowing traditional investors to gain exposure through conventional brokerage accounts.  Ethereum's roadmap focuses on dramatically increasing transaction capacity to over 100,000 per second, reducing confirmation times, and enhancing decentralization while maintaining security against future threats like quantum computing.

Ethereum

Ethereum is drawing significant attention for its strong network fundamentals, including rising staking demand and its growing role as infrastructure for AI agents and financial applications. The community is debating its resilience amidst market volatility, with ongoing institutional interest and ETF inflows contrasting with concerns about price manipulation.

Codatta

XNY is capturing significant community attention due to its strong performance and ability to recover quickly from broader market dips, leading to widespread speculation about a potential 'next leg' higher for the Codatta AI/data utility token.

Aerodrome Finance is a next-generation AMM designed to serve as Base's central liquidity hub, combining a powerful liquidity incentive engine, vote-lock governance model, and friendly user experience. Aerodrome inherits the latest features from Velodrome V2.

Aerodrome Finance

Aerodrome Finance (AERO) is generating buzz with its recent Robinhood listing and upcoming cross-chain expansion via a Velodrome merger, sparking community debate about its potential as Base's primary decentralized exchange, especially as its protocol revenue continues to exceed token emissions.

Gorilla Technology Group, Inc. engages in the provision of video intelligence, Internet of Things (IoT) security, edge AI data analytics, and operational technology security solutions and services in Asia Pacific. It operates through the following segments: Video IoT, Security Convergence, and Other. The company was founded by Spincer Koh in May 2001 and is headquartered in London, the United Kingdom.

Gorilla Technology Group Inc

Gorilla Technology Group is trending as conflicting institutional movements, with Alyeska exiting while major players like BlackRock accumulate shares, intensify a polarized debate among investors over alleged stock manipulation versus the company's strong AI infrastructure contract pipeline and anticipated earnings.

Karyopharm Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. The company was founded by Joseph Araujo, Ronald A. DePinho, Pamela A, Silver, Giulio Draetta, Michael G. Kauffman, and Sharon Shacham on December 22, 2008, and is headquartered in Newton, MA.

Karyopharm Therapeutics Inc

Karyopharm Therapeutics is seeing heightened trading volume and bullish options activity driven by anticipation for upcoming binary Phase 3 trial readouts in Myelofibrosis and Endometrial Cancer. This comes despite significant community criticism regarding its leadership's perceived mismanagement and extensive shareholder value destruction.

Grayscale Investments LLC - Grayscale Bitcoin Trust

Grayscale Bitcoin Trust

GBTC is trending as the community anticipates a significant 'parabolic' surge for Bitcoin, drawing parallels to gold's recent strength amidst ongoing discussions of market manipulation and dollar devaluation. Many view current levels as 'undervalued' and a 'buy the dip' opportunity, despite some calls for a 'crypto winter'.

statis crypto Watchlist

Bitcoin

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

U.S.-listed shares of Ascendis Pharma climbed more than 7% in Thursday’s premarket session, setting the stage for their best open since early January.Late on Wednesday, the company reported better-than-expected fourth-quarter results and announced a share repurchase program.The Danish biopharma company posted Q4 revenue of €173.92 million ($180.6 million), up from €137.7 million a year ago, while its loss per share narrowed to €0.64 from €1.53.&nbsp;CEO Jan Mikkelsen said the company is “positioned to continue strong revenue growth in 2025 and beyond,” citing Yorvipath’s early U.S. momentum and SkyTROFA’s leadership in the domestic growth hormone market.&nbsp;Ascendis also confirmed plans to submit regulatory filings for TransCon CNP as a treatment for children with achondroplasia.The board also authorized up to $18.25 million for repurchases of its American depository receipt shares.&nbsp;On Stocktwits, message volume for Ascendis spiked, with several posts indicating optimism over the guidance and Yorvipath’s growth.<stembedurl>https://stocktwits.com/Pika_Capital/message/604018998</stembedurl><stembedurl>https://stocktwits.com/CrispDry/message/603879227</stembedurl>BofA Securities on Thursday lowered its price target on Ascendis shares to $192 from $203 while maintaining a ‘Buy’ rating.&nbsp;The firm adjusted its 2025 Yorvipath sales forecast downward, expecting a more backloaded ramp, but reiterated Ascendis as a “top pick for 2025” with projected peak sales of €2.9 billion.Yorvipath recently became the only approved U.S. treatment for hypoparathyroidism after Takeda discontinued Natpara production due to supply issues.Despite the day’s gains, Ascendis shares remain down over 10% in the past year and trade about 54% below the average analyst target of $193.49, according to Koyfin data.&nbsp;&nbsp;The company’s stock has a short interest of 5.4%.(1 Euro=$1.04)For updates and corrections, email newsroom[at]stocktwits[dot]com.

Ascendis Pharma Eyes Best Open In A Month After Q4 Print, But BofA Cuts Price Target: Retail Gets Buzzing

The brokerage adjusted its 2025 Yorvipath sales forecast downward, expecting a more backloaded ramp.

Equity

The brokerage adjusted its 2025 Yorvipath sales forecast downward, expecting a more backloaded ramp.


Shares of Keros Therapeutics (KROS) plunged nearly 20% in premarket trading on Wednesday, poised to hit an all-time low after the company voluntarily halted dosing in the mid-stage trial of its intercept drug for pulmonary arterial hypertension (PAH).&nbsp;The trial was terminated early following safety concerns, as Keros cited new cases of pericardial effusion (fluid buildup around the heart) as the reason for halting dosing.The company said that patients enrolled in the trial will continue to be monitored through end-of-study visits.CEO Jasbir Seehra stated, "While we are disappointed, patient safety is always our top priority.”“We continue to work with the investigators, the U.S. Food and Drug Administration (“FDA”) and other relevant regulatory authorities, and we look forward to analyzing and presenting TROPOS topline clinical data in the future,” he added.The latest development marks the second major setback for the trial; in December, Keros halted dosing at higher levels (3.0 mg/kg and 4.5 mg/kg) due to similar safety issues, resulting in a 73% single-day drop in the stock.Investor sentiment on Stocktwits initially turned 'bearish' from 'bullish' a day ago, with message volume spiking enough to push Keros into the platform's top trending list.&nbsp;While some users argued the stock was oversold, the majority expressed concerns over a lack of support as the price dipped below $10.<stembedurl>https://stocktwits.com/paid2win/message/600100720</stembedurl><stembedurl>https://stocktwits.com/_DaddyDanii_/message/600096956</stembedurl><stembedurl>https://stocktwits.com/muntasser/message/600096543</stembedurl>Keros reported $530.7 million in cash and equivalents as of the end of&nbsp;the third quarter (Q3) of 2024, with debt totaling $19.3 million. This gives it a relatively solid cash runway despite recent challenges.The company's stock declined nearly 60% in 2024 and lost an additional 21% in 2025.The road ahead appears challenging as retail optimism wanes and Wall Street looks for clarity on Keros' plans for cibotercept and other pipeline assets.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Stock market down on a black background. | Image source: Yuichiro Chino via Getty Images

Keros Therapeutics Stock Heads For Record Low After Dosing Halt In Pulmonary Disease Trial, Retail Buzz Spikes

The company’s stock declined nearly 60% in 2024 and has lost an additional 21% in 2025, with this latest setback further dampening investor confidence.

Tema ETF Trust - Tema Heart & Health ETF

3%+ above current levels

Up 0–3%

Flat to down 3%

Down 3%+

The Nasdaq 100 continues to hinge on mega-cap tech and AI strength. With rate expectations shifting and valuations stretched, even a 3% move could signal a bigger trend. Is momentum building, or fading?

HRTS
GLP-1, Obesity & Cardiometabolic ETF

Feed

News

Sentiment

Fundamentals

Info

Latest HRTS News

HRTSGLP-1, Obesity & Cardiometabolic ETF